RP2.H.iPSC.3

General

Cell Line

hPSCreg name RIi009-A
Cite as:
RIi009-A (RRID:CVCL_C916)
Alternative name(s)
RP2.H.iPSC.3
Cell line type Human induced pluripotent stem cell (hiPSC)
Similar lines
LUMCi056-A-1
(LUMC0128iCRB01 heterozygote CRISPR corrected isogenic clone 02, iso02LUMC0128iCRB01)
Donor's gene variants:
CRB1, CRB1
Donor diseases:
Retinitis Pigmentosa
WTSIi694-A
(HPSI0816i-oemk_6)
Donor diseases:
Retinitis pigmentosa
UNEWi004-A
(PRPF31 SH)
Donor's gene variants:
PRPF31
Donor diseases:
Retinitis pigmentosa
UNEWi005-A
(PRPF31 RH)
Donor's gene variants:
PRPF31
Donor diseases:
Retinitis pigmentosa
WTSIi463-A
(HPSI0716i-yibs_1)
Donor diseases:
Retinitis pigmentosa
CIRMi508-A
(CW70323)
Donor diseases:
retinitis pigmentosa
WTSIi659-B
(HPSI1116i-wakr_6)
Donor diseases:
Retinitis pigmentosa
WTSIi610-A
(HPSI1116i-naum_5)
Donor diseases:
Retinitis pigmentosa
CIRMi519-A
(CW70342)
Donor diseases:
retinitis pigmentosa
MUi038-A
(EYS mutation)
Donor diseases:
retinitis pigmentosa
FRIMOi001-A
(RP1_FiPS4F1.6)
Donor diseases:
Retinitis Pigmentosa
LUMCi055-A
(CRB1 patient 117 compound heterozygous 2983G>T p.(Glu995*) c.1892A>G, p.(Tyr631Cys), LUMC0117iCRB01)
Donor's gene variants:
CRB1, CRB1
Donor diseases:
Retinitis Pigmentosa
CIRMi531-A
(CW70356)
Donor diseases:
retinitis pigmentosa
LUMCi056-A
(CRB1 patient 128 compound heterozygous c.2843G>A p.(Cys948Tyr) and c.3122T>C p.(Met1041Thr), LUMC0128iCRB01)
Donor's gene variants:
CRB1, CRB1
Donor diseases:
Retinitis Pigmentosa
CABi002-A
(OF0176-EYS02-C7, EYS02-MiPS4F7)
Donor diseases:
Retinitis Pigmentosa
CIRMi542-A
(CW70373)
Donor diseases:
retinitis pigmentosa
WTSIi659-A
(HPSI1116i-wakr_3)
Donor diseases:
Retinitis pigmentosa
NUIGi027-A
(RP001C8)
Donor diseases:
Retinitis Pigmentosa
NUIGi028-A
(RP002C12)
Donor diseases:
Retinitis Pigmentosa
NUIGi029-A
(RP003C12)
Donor diseases:
Retinitis Pigmentosa
WTSIi463-B
(HPSI0716i-yibs_3)
Donor diseases:
Retinitis pigmentosa
WTSIi691-A
(HPSI1116i-eiyy_1)
Donor diseases:
Retinitis pigmentosa
WTSIi693-A
(HPSI1116i-zies_2)
Donor diseases:
Retinitis pigmentosa
UNEWi001-A
(UNEW001Ai)
Donor's gene variants:
PRPF31
Donor diseases:
Retinitis pigmentosa
UNEWi002-A
(UNEW002Ai, PRPF31 AW)
Donor's gene variants:
PRPF31, PRPF31
Donor diseases:
Retinitis pigmentosa
UNEWi003-A
(PRPF31-HD)
Donor diseases:
Retinitis pigmentosa
WTSIi698-A
(HPSI1116i-aimh_5)
Donor diseases:
Retinitis pigmentosa
WTSIi713-A
(HPSI0816i-xoga_7)
Donor diseases:
Retinitis pigmentosa
WTSIi693-B
(HPSI1116i-zies_6)
Donor diseases:
Retinitis pigmentosa
WTSIi698-B
(HPSI1116i-aimh_3)
Donor diseases:
Retinitis pigmentosa
WTSIi688-B
(HPSI1116i-wiau_4)
Donor diseases:
Retinitis pigmentosa
WTSIi613-B
(HPSI1116i-rafd_1)
Donor diseases:
Retinitis pigmentosa
WTSIi613-A
(HPSI1116i-rafd_4)
Donor diseases:
Retinitis pigmentosa
ESi077-A
(CABi001-A, PRPF31-MiPS4F3)
Donor's gene variants:
PRPF31, PRPF31
Donor diseases:
Retinitis Pigmentosa
CIRMi525-A
(CW70348)
Donor diseases:
retinitis pigmentosa
FRIMOi002-A
(RP2_FiPS4F2.2)
Donor diseases:
Retinitis Pigmentosa
FRIMOi005-A
(RP3_FiPS4F11)
Donor diseases:
Retinitis Pigmentosa
UNEWi027-A
(F116)
Donor's gene variants:
PRPF31
Donor diseases:
Retinitis pigmentosa
WTSIi713-B
(HPSI0816i-xoga_12)
Donor diseases:
Retinitis pigmentosa
WTSIi688-A
(HPSI1116i-wiau_1)
Donor diseases:
Retinitis pigmentosa
RIi012-A
(RP.1.H.iPSC.2)
Donor diseases:
Retinitis pigmentosa
Last update 30th August 2022
User feedback
No feedback available yet.

Login to share your feedback, experiences or results with the research community.

Provider

Generator Royan Institute (RI)
Derivation country Iran

External Databases

Cellosaurus CVCL_C916
Wikidata Q54951130

General Information

Publications
* Is the cell line readily obtainable for third parties?
Yes

Donor Information

General Donor Information

Sex male

Phenotype and Disease related information (Donor)

Diseases A disease was diagnosed.
The donor is affected.
Disease associated phenotypes
  • per inv(9)(p11q12)

Ethics

Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? Yes
Was the consent voluntarily given? Yes
Has the donor been informed that participation will not directly influence their personal treatment? Yes
Can you provide us with a copy of the Donor Information Sheet provided to the donor? No
Please provide contact information of the holder of the original Donor Information Sheet.
Do you (Depositor/Provider) hold the original Donor Consent Form? Yes
How may genetic information associated with the cell line be accessed?
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used?

hIPSC Derivation

General

Reprogramming method

Vector type Integrating
Vector Virus (Retrovirus)
Genes
Is the used vector excisable?
Unknown
Absence of reprogramming vector(s)?
Unknown
Reprogramming vectors silenced?

Vector free reprogramming

Other

Derived under xeno-free conditions
Unknown
Derived under GMP?
Unknown
Available as clinical grade?
Unknown

Culture Conditions

Surface coating Matrigel/Geltrex
CO2 Concentration 5 %
Medium Other medium:
Base medium: DMEM F/12
Main protein source: Knock-out serum replacement
Serum concentration: 20 %
Supplements
L-glutamine 2 mM
β-mercaptoethanol 0.1 mM
nonessential amino acids 1 %
penicillin 100 units/ml
streptomycin 100 µg/ml
insulin-transferrin-selenite
bFGF

Characterisation

Analysis of Undifferentiated Cells
Marker Expressed Immunostaining RT-PCR Flow Cytometry Enzymatic Assay Expression Profiles
Alkaline Phosphatase
Yes
NANOG
Yes
POU5F1 (OCT-4)
Yes
SSEA-3
Yes
SSEA-4
Yes
TRA 1-60
Yes
TRA 1-81
Yes
SOX2
Yes

Genotyping

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
Yes
46XY

Other Genotyping (Cell Line)